Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2011-10-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2011. It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet summaries, as well as detailed management commentary on business operations, R&D projects, and strategic outlook. It is not a mere announcement (RPA) or a short summary, but a full quarterly/interim financial report. 9M 2011
2011-10-25 Swedish
Interim / Quarterly Report 2011
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY–SEPTEMBER 2011' and contains detailed financial statements, including net sales, net loss, earnings per share, and cash flow data for the specified period. It also includes management commentary, project updates, and a summary of key financial information. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2011
2011-10-25 English
KARO BIO FÖRBEREDER AVKNOPPNING AV PREKLINISK VERKSAMHET
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 25, 2011, announcing that Karo Bio AB is preparing to spin off its preclinical operations into a separate subsidiary. This action involves restructuring, potential future financing for the new entity, and a planned detailed proposal to be presented later. The core subject is a significant change in the company's structure and financing strategy related to its assets. This aligns best with the 'Capital/Financing Update' (CAP) category, as it details a major capital restructuring event (a spin-off) and future financing plans for the new entity. It is not a full annual report (10-K), an earnings release (ER), or a management discussion (MDA), but rather a strategic announcement about corporate structure and capital allocation.
2011-10-25 Swedish
KARO BIO PREPARES SPIN-OFF OF PRECLINICAL DEVELOPMENT
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a strategic corporate action: the preparation for spinning off the company's preclinical development activities into a separate, autonomous subsidiary. This action directly relates to changes in the company's structure, financing strategy (seeking new owners for the subsidiary), and capital allocation. It is not a full financial report (10-K or IR), an earnings release (ER), a dividend notice (DIV), or a director's dealing report (DIRS). Since the core subject is a major structural change involving financing and ownership separation, the most appropriate category is Capital/Financing Update (CAP). Although it mentions a proposal for change of name will be submitted to the general meeting, the primary focus is the spin-off itself, which is a capital structure event.
2011-10-25 English
Per Bengtsson appointed CEO
Board/Management Information Classification · 99% confidence The document is a press release dated October 24, 2011, announcing that the Board of Directors of Karo Bio AB has appointed Per Bengtsson as CEO. This constitutes an announcement of a change in senior management. Based on the definitions, this aligns perfectly with the 'Board/Management Information' category.
2011-10-24 English
Per bengtsson utsedd till vd
Board/Management Information Classification · 98% confidence The document is a press release dated October 24, 2011, announcing that the Board of Directors of Karo Bio AB has appointed Per Bengtsson as the new CEO, succeeding his role as interim CEO. This directly concerns a change in senior management. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is short and clearly an announcement, not a comprehensive report.
2011-10-24 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.